Skip to content

Improved Prescribing for Older Nursing Home Patients

Improving Medication Prescription in the contExt of Advance Care Planning for paTients Receiving Long Term nUrSing Home Care

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06731361
Acronym
IMPETUS
Enrollment
450
Registered
2024-12-12
Start date
2024-09-10
Completion date
2025-12-01
Last updated
2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advance Care Planning, Decision Making, Medication Reviews, Nursing Home Residents, Older People, Prescribing, Prescribing Practices

Keywords

limited life expectancy, ReNeWAL criteria (adjusted STOPP/START criteria), decision making involvement, appropriate prescribing, Cluster randomised trial, Educational intervention, Prescribing practices

Brief summary

Research aim: To investigate the effect of training health care professionals in medication assessments on the medication use of nursing home residents with a limited life expectancy (\< 1.5-2 years). The core of the training is to tailor medication use to (palliative) treatment goals of nursing home residents. Design: A cluster randomized controlled trial on long term care wards in nursing homes, with the nursing home care organisations as unit of randomisation. The investigators intent to include 6 organisations and 450 nursing home patients. The research starts in september and lasts 1 year and 3 months. Eligible patients are nursing home patients of 65 years and older with a limited life expectancy (\< 1.5-2 year) of long term care wards. Intervention: The intervention includes a method in which healthcare professionals (medical practitioner, pharmacist and care worker) are trained to tailor medication to the (palliative) treatment goals of nursing home patients with a limited life expectancy. The training consists of 2 components: 1) medication assessment, and 2) advance care planning (ACP). In the intervention group, healthcare professionals receive the training in combination with supporting tools and educational materials, in the control group care continues as normal. The allocation ratio for control and intervention groups is 1:1. A process evaluation will take place simultaneously with the intervention study. Data collection takes place before the start of the intervention (T0), after 6 months (T1) and after 12 months (T2). Outcome measures: The primary outcome measure is potential under- and over-treatment with medication. The secondary outcome measure is experienced involvement in decision-making (measured with a short questionnaire based on the revised PATD (patients' attitude towards deprescribing)). Tertiary outcome measures are: quality of life, deaths, falls, hospital admissions/acute first aid referrals and pain. Discussion: The intervention is expected to result in a decrease in chronic and preventive medication prescriptions, an increase in medication for symptom treatment and more involvement (and satisfaction) of the nursing home resident in decision-making, without adverse effects.

Detailed description

Additional information on the method: We included 2 nursinghome organizations in september, 2 in october, and 3 in november.

Interventions

COMBINATION_PRODUCTSystematic multidisciplinary medication review + ACP (SMMR+)

The intervention is a training in medication assessment. The goal is to align prescription with the treatment goals of nursing home patients which are set in advance care planning conversations. The training consists of 2 components: 1. Medication assessment with the use of the ReNeWAL criteria (adjusted STOPP/START criteria, tailored to nursing home patients with a limited life expectancy) 2. Advance care planning component. Discussing medication in line with the treatment goals set in advance care planning conversations. Healthcare professionals receive the training in combination with supporting tools (pocket card) and educational material (the ReNeWAL criteria and PowerPoint slides of the training if requested). Also, intervision moments are planned.

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
Amsterdam UMC, location VUmc
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Masking description

Not possible due to the type of intervention

Intervention model description

Cluster randomised controlled trial with 2 arms: intervention and control. Ratio 1:1. 2 clusters start in september, 2 clusters start in october and 2 clusters start in november.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Nursing home patients: * Age 65years and above * Living at long term care wards in nursing homes * Living at a long term care ward for at least 4 weeks before start of the study

Exclusion criteria

* Temporary nursing home patients (i.e. geriatric rehabilitation or end-of-life/hospice care) * Life expectancy \< 4 weeks * Life expectancy clearly \> 1.5 - 2 years (i.e. patients with Huntingtons disease)

Design outcomes

Primary

MeasureTime frameDescription
Potential under- and overprescribingat baseline - 6 months - 12 monthsPotential under- and overprescribing

Secondary

MeasureTime frameDescription
Experienced involvement in decision-makingAt baseline and 2-4 weeks after the medication reviewExperienced involvement in decision-making measured with a questionnaire

Other

MeasureTime frameDescription
Adverse outcomesat baseline - 6 months - 12 monthsAdverse outcomes, such as: deaths, falls, hospital admissions/acute referrals, measured over the previous 6 months. (Only for ' deaths' not possible at baseline.)
QOL (Quality of life)at baseline - 6 months - 12 monthsQuality of life measured with the EuroQol questionnaire (EQ-5D)
Process evaluationThrough 1 year and 3 monthsQualitative and quantitative data
Pain assessmentat baseline - 6 months - 12 monthsmeasured with the pain items of the Resident Assessment Instrument for Long-term Care Facilities (RAI-LTCF) questionnaire
Social wellbeingat baseline - 6 months - 12 monthsMeasured with Revised index for social engagement (RISE) questionnaire

Countries

Netherlands

Contacts

Primary ContactMarlies Dijk, MD
m.dijk5@amsterdamumc.nl020-4445785
Backup ContactEefje Sizoo, MD, PhD
e.sizoo@amsterdamumc.nl020-4445785

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026